Clinical stage biopharma Kezar Life Sciences is discontinuing its lupus nephritis (LN) clinical programme following the death ...

Belimumab demonstrates notable efficacy for enhancing treatment outcomes among adults with active systemic lupus erythematosus when added to standard therapy. Belimumab demonstrates notable efficacy ...

particularly glucocorticoids Using antimalarials and immunosuppressives both to control disease in the long term and avoid 'spare' glucocorticoids Belimumab Minor arthritis, mild pleurisy NSAIDs ...

with newer medicines like GSK's Benlysta (belimumab), AstraZeneca's Saphnelo (anifrolumab), and Otsuka's Lupkynis (voclosporin). For Biogen, dapirolizumab pegol is part of a push into the ...

It was approved in the US with a similar label last year after priority review, becoming the first oral alternative to GSK's injectable anti-BLyS/BAFF antibody Benlysta (belimumab) for the ...

Panelists discuss the differences in efficacy and safety profiles between belimumab and voclosporin for lupus nephritis (LN) and how payers are evaluating their value, including considerations of cost ...

Fan et al. demonstrated, in real-world settings, achieving early lupus low disease activity state (LLDAS) in systemic lupus erythematosus (SLE) patients treated with telitacicept or belimumab is ...

Panelists discuss the challenges patients face in accessing lupus nephritis treatment and the resources available to support ...